A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Inclusion criteria

• . Male or female aged at least 18 years.
• . Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.
• . Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.
• . Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.
• . Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).
• . Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
• . Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.
• . World Health Organisation Performance Status of 0 to 1.

Exclusion criteria